Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

KW Chew, C Moser, ES Daar, DA Wohl, JZ Li… - Nature …, 2022 - nature.com
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

RL Gottlieb, A Nirula, P Chen, J Boscia, B Heller… - Jama, 2021 - jamanetwork.com
Importance Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide.
Neutralizing antibodies are a potential treatment for COVID-19. Objective To determine the …

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19

P Chen, G Datta, Y Grace Li, J Chien… - Clinical …, 2021 - Wiley Online Library
Therapeutics for patients hospitalized with coronavirus disease 2019 (COVID‐19) are
urgently needed during the pandemic. Bamlanivimab is a potent neutralizing monoclonal …

Bamlanivimab plus etesevimab in mild or moderate Covid-19

M Dougan, A Nirula, M Azizad… - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over …

Real-world experience of bamlanivimab for coronavirus disease 2019 (COVID-19): a case-control study

RN Kumar, EL Wu, V Stosor, WJ Moore… - Clinical Infectious …, 2022 - academic.oup.com
Abstract Background Coronavirus disease 2019 (COVID-19) has strained healthcare
systems with patient hospitalizations and deaths. Anti-spike monoclonal antibodies …

Safety and efficacy of combination SARS-CoV-2 neutralizing monoclonal antibodies amubarvimab plus romlusevimab in nonhospitalized patients with COVID-19

TH Evering, KW Chew, MJ Giganti, C Moser… - Annals of internal …, 2023 - acpjournals.org
Background: Development of safe and effective SARS-CoV-2 therapeutics is a high priority.
Amubarvimab and romlusevimab are noncompeting anti–SARS-CoV-2 monoclonal …

[HTML][HTML] An EUA for Bamlanivimab-A monoclonal anti-body for COVID-19

M Orders - Med Lett Drugs Ther, 2020 - secure.medicalletter.org
The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly)
has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently …

A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2

R Nathan, I Shawa, I De La Torre, JM Pustizzi… - Infectious diseases and …, 2021 - Springer
The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …

Endogenous antibody responses to SARS-CoV-2 in patients with mild or moderate COVID-19 who received bamlanivimab alone or bamlanivimab and etesevimab …

L Zhang, J Poorbaugh, M Dougan, P Chen… - Frontiers in …, 2021 - frontiersin.org
Background Neutralizing monoclonal antibodies (mAbs) to SARS-CoV-2 are clinically
efficacious when administered early, decreasing hospitalization and mortality in patients …

Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019

R Ganesh, LM Philpot, DM Bierle… - The Journal of …, 2021 - academic.oup.com
Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild
to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the …